Action AKRO AKERO THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Akero Therapeutics, Inc.

Actions

AKRO

US00973Y1082

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 07/06/2024 		Varia. 5j. Varia. 1 janv.
23,02 USD +7,92 % Graphique intraday de Akero Therapeutics, Inc. +22,32 % -1,41 %
15/05 AKERO THERAPEUTICS, INC. : Evercore ISI toujours positif ZM
10/05 La perte nette d'Akero Therapeutics au premier trimestre s'aggrave ; les liquidités devraient permettre de financer les opérations jusqu'au second semestre 2027 MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
Certain Restricted Stock Units of Akero Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2024.
Certain Stock Options of Akero Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2024.
Certain Common Stock of Akero Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2024.
Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.
ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Kirby McInerney LLP Notifies Akero Therapeutics, Inc. (AKRO) Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
AKERO THERAPEUTICS CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AKRO
  4. Actualités Akero Therapeutics, Inc.
  5. Autres langues